Dyax Corp. to Host Second Quarter 2004 Earnings Call and Webcast.CAMBRIDGE, Mass. -- Dyax Corp. (Nasdaq:DYAX) will host a conference call, webcast and question and answer session on Wednesday, August 4, 2004, to discuss financial results and company progress for the second fiscal quarter ended June 30, 2004.
Date: Wednesday, August 4, 2004
Time: 10:00 a.m. EST
Telephone Access: Domestic callers, dial 800-967-7138
International callers, dial 719-457-2628
Online Access: Go to the Investor Relations section of the Dyax
website (www.dyax.com) and follow instructions
for live webcast. Participants may register in
advance.
A replay of the conference call will be available through August 18, 2004 and can be accessed by dialing 888-203-1112. International callers should dial 719-457-0820. The replay passcode I.D. for all callers is 151326. The webcast will be archived on the Dyax website for an indefinite period of time. Dyax Corp. Dyax Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of antibodies, small proteins and peptides as therapeutic products for unmet medical needs, particularly in the areas of inflammation and oncology. Two recombinant small proteins discovered by Dyax are currently in phase II clinical trials Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II . In collaboration with Genzyme Corporation, Dyax has completed a phase II, 48-patient placebo-controlled clinical trial of DX-88 for the treatment of hereditary angioedema Hereditary angioedema A complement deficiency characterized by lymphatic vessel blockages that cause temporary swelling (edema) of areas of the skin, mucous membranes, and, sometimes, internal organs. Mentioned in: Complement Deficiencies (HAE) and is currently conducting an open-label repeat dose phase II clinical trial with investigational sites in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and worldwide. Dyax has also completed phase I/II trials for the potential use of DX-88 during open-heart surgery open-heart surgery Any surgical procedure opening the heart and exposing one or more of its chambers, most often to repair valve disease or correct congenital heart malformations (see congenital heart disease). , specifically on-pump coronary artery bypass grafting coronary artery bypass graft n. Abbr. CABG A surgical procedure in which a section of vein or other conduit is grafted between the aorta and a coronary artery below the region of an obstruction in that artery. (CABG CABG coronary artery bypass graft. CABG abbr. coronary artery bypass graft CABG Coronary artery bypass graft, see there ) procedures. Dyax's collaborator for DX-890, Debiopharm SA, has completed phase IIa clinical trials for the potential treatment of cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. . Both DX-88 and DX-890 were identified using Dyax's patented phage display phage display n. A technique using recombinant DNA technology to create bacteriophages with a desired peptide embedded in the surface of their protein shells. technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. This powerful discovery engine is being used to build a pipeline of drug candidates that may be advanced into clinical development by Dyax and/or in partnership with other companies. Dyax leverages its technology broadly with over 75 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. For online information about Dyax Corp., please visit www.dyax.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion